These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17243139)

  • 1. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease.
    Gao Q; Meijer MJ; Schlüter UG; van Hogezand RA; van der Zon JM; van den Berg M; van Duijn W; Lamers CB; Verspaget HW
    Inflamm Bowel Dis; 2007 Jun; 13(6):693-702. PubMed ID: 17243139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stromelysin-1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn's disease patients treated with infliximab.
    Di Sabatino A; Saarialho-Kere U; Buckley MG; Gordon JN; Biancheri P; Rovedatti L; Corazza GR; Macdonald TT; Pender SL
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1049-55. PubMed ID: 19357521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease.
    de Bruyn M; Arijs I; De Hertogh G; Ferrante M; Van Assche G; Rutgeerts P; Vermeire S; Opdenakker G
    J Crohns Colitis; 2015 Dec; 9(12):1079-87. PubMed ID: 26351381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease.
    Meijer MJ; Mieremet-Ooms MA; van Duijn W; van der Zon AM; Hanemaaijer R; Verheijen JH; van Hogezand RA; Lamers CB; Verspaget HW
    Inflamm Bowel Dis; 2007 Feb; 13(2):200-10. PubMed ID: 17206679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease.
    Mäkitalo L; Rintamäki H; Tervahartiala T; Sorsa T; Kolho KL
    Scand J Gastroenterol; 2012 Jul; 47(7):785-94. PubMed ID: 22519363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease.
    Bouchaud G; Mortier E; Flamant M; Barbieux I; Plet A; Galmiche JP; Jacques Y; Bourreille A
    Gastroenterology; 2010 Jun; 138(7):2378-87. PubMed ID: 20188102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies.
    Di Sabatino A; Pender SL; Jackson CL; Prothero JD; Gordon JN; Picariello L; Rovedatti L; Docena G; Monteleone G; Rampton DS; Tonelli F; Corazza GR; MacDonald TT
    Gastroenterology; 2007 Jul; 133(1):137-49. PubMed ID: 17631138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients.
    Lindberg J; af Klint E; Catrina AI; Nilsson P; Klareskog L; Ulfgren AK; Lundeberg J
    Arthritis Res Ther; 2006; 8(6):R179. PubMed ID: 17134501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF-alpha antibody (infliximab) therapy supports the recovery of eNOS and VEGFR2 protein expression in endothelial cells.
    Altorjay I; Veréb Z; Serfozo Z; Bacskai I; Bátori R; Erdodi F; Udvardy M; Sipka S; Lányi Á; Rajnavölgyi É; Palatka K
    Int J Immunopathol Pharmacol; 2011; 24(2):323-35. PubMed ID: 21658307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
    Ricciardelli I; Lindley KJ; Londei M; Quaratino S
    Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis.
    de Bruyn M; Arijs I; Wollants WJ; Machiels K; Van Steen K; Van Assche G; Ferrante M; Rutgeerts P; Vermeire S; Opdenakker G
    Inflamm Bowel Dis; 2014 Jul; 20(7):1198-207. PubMed ID: 24871805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases.
    Gao Q; Meijer MJ; Kubben FJ; Sier CF; Kruidenier L; van Duijn W; van den Berg M; van Hogezand RA; Lamers CB; Verspaget HW
    Dig Liver Dis; 2005 Aug; 37(8):584-92. PubMed ID: 15869913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease.
    Miheller P; Muzes G; Zagoni T; Toth M; Racz K; Tulassay Z
    Dig Dis; 2006; 24(1-2):201-6. PubMed ID: 16699279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-MMP-9 Antibody: A Promising Therapeutic Strategy for Treatment of Inflammatory Bowel Disease Complications with Fibrosis.
    Goffin L; Fagagnini S; Vicari A; Mamie C; Melhem H; Weder B; Lutz C; Lang S; Scharl M; Rogler G; Chvatchko Y; Hausmann M
    Inflamm Bowel Dis; 2016 Sep; 22(9):2041-57. PubMed ID: 27542125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of infliximab on tumor necrosis factor-alpha-induced alterations in retinal microvascular endothelial cells and retinal pigment epithelial cells.
    Li H; Yoneda M; Takeyama M; Sugita I; Tsunekawa H; Yamada H; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):549-56. PubMed ID: 21054185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.